Related Experiment Videos
Drugs or diet: do they protect against degenerative cardiovascular disease?
1Medizinische Klinik und Poliklinik A der Universität Düsseldorf, F.R.G.
Insights
Aspirin (acetylsalicylic acid) is widely used for cardiovascular disease prevention, but safer alternatives like omega-3 fatty acids are emerging. These dietary changes may offer new ways to prevent vascular issues.
Area of Science:
- Cardiovascular Pharmacology
- Nutritional Science
- Thrombosis Research
Background:
- Aspirin (acetylsalicylic acid, ASA) is a common nonsteroidal anti-inflammatory drug frequently used in clinical trials for arterial cardiovascular diseases.
- Its use aims to prevent myocardial infarction, reduce platelet aggregation, and improve outcomes in conditions like unstable angina and after bypass surgery.
- Concerns about aspirin's gastrointestinal side effects drive interest in alternative methods for inhibiting platelet eicosanoid metabolism.
Purpose of the Study:
- To explore the role of aspirin in preventing thromboembolic complications and platelet deposition on artificial surfaces.
- To investigate less toxic alternatives to aspirin for inhibiting platelet metabolism, focusing on omega-3 fatty acids.
- To examine whether dietary polyunsaturated fatty acids influence platelet metabolism or if leukocytes/monocytes mediate the effects of anti-platelet therapies.
Main Methods:
- Review of early observations and large clinical trials on aspirin's effects on myocardial infarction and platelet aggregation.
- Investigation into the potential of omega-3 fatty acid substitution for competitive inhibition of arachidonic acid metabolism.
- Analysis of fish-oil diet results to question the primary mediators (platelets vs. leukocytes/monocytes) of anti-platelet actions.
Main Results:
- Aspirin remains a primary drug for arterial vascular disorders despite potential side effects.
- Omega-3 fatty acids present a promising, less toxic alternative by competitively inhibiting arachidonic acid metabolism.
- Fish-oil diet studies suggest a potential role for leukocytes/monocytes in mediating cardiovascular protective effects.
Conclusions:
- While aspirin is established, its side effects necessitate exploring safer alternatives like omega-3 fatty acids.
- Dietary interventions, such as omega-3 supplementation, may offer a novel approach for primary or adjunctive prophylaxis of vascular disease.
- Further research is needed to elucidate the precise mechanisms and mediators of anti-platelet and dietary interventions in cardiovascular health.
Abstract:
Early observations that the regular use of aspirin (acetylsalicylic acid, ASA), a nonsteroidal anti-inflammatory agent, seemed to protect against myocardial infarction and reduce platelet aggregation made this substance the most frequently used drug in large clinical trials. The objectives of these studies were to reduce thromboembolic complications in arterial cardiovascular diseases (prevention of myocardial infarction in unstable angina, secondary prevention of acute myocardial infarction, and increased patency of aortocoronary bypass grafts) and to reduce platelet deposition on artificial surfaces (artificial heart valves and hemodialysis shunts). Despite the recent synthesis of more selective inhibitors of arachidonic acid metabolism in blood platelets, and a multitude of questions concerning optimal dose, schedule, and mode of action that still remain open, ASA continues to be the most frequently used drug in arterial vascular disorders. Because of the frequent and potentially serious side effects of aspirin, mainly on the gastrointestinal tract, less toxic ways of inhibiting eicosanoid metabolism in blood platelets are attracting more and more interest. Among these, the alimentary substitution of omega-3 fatty acids for a competitive inhibition of the omega-6-arachidonic acid metabolism seems the most promising. Results with fish-oil diet raise the question of whether substitution of polyunsaturated lipid acids influence only platelet metabolism, or whether the action of "anti-platelet" drugs or diet in cardiovascular disorders is mediated primarily by leukocytes or monocytes. This new dietary principle, which possibly corrects only a poor alimentary habit of civilization, could open simple and adequate ways for even a primary prophylaxis of vascular disease by diet alone or, at least for therapeutic aims, in combination with drugs.